Download PDF
Thromb Haemost 1990; 64(01): 032-037
DOI: 10.1055/s-0038-1647149
Original Article
Schattauer GmbH Stuttgart

Partial Neutralization of a Lupus Anticoagulant by Human Immunoglobulin[*]

L O Carreras
The Haemostasis and Thrombosis Section, Division of Haematology, Hospital de Clinicas, University of Buenos Aires
,
G N Pérez
The Haemostasis and Thrombosis Section, Division of Haematology, Hospital de Clinicas, University of Buenos Aires
,
M E Martinuzzo
The Haemostasis and Thrombosis Section, Division of Haematology, Hospital de Clinicas, University of Buenos Aires
,
I Malan-Borel
*   Institute for Studies on Humoral Immunity, IDEHU (CONICET-UBA), Faculty of Pharmacy and Biochemistry University of Buenos Aires, Argentina
,
A Malbrän
The Haemostasis and Thrombosis Section, Division of Haematology, Hospital de Clinicas, University of Buenos Aires
,
P B Said
The Haemostasis and Thrombosis Section, Division of Haematology, Hospital de Clinicas, University of Buenos Aires
› Author Affiliations
Further Information

Publication History

Received 26 September 1989

Accepted after revision 02 April 1990

Publication Date:
25 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In a patient with a Lupus Anticoagulant (LA) and recurrent fetal loss, we observed a significant shortening of the APTT after high-dose intravenous immunoglobulin infusion (IVIg).

The LA activity present in patient’s serum and purified IgG was partially neutralized by IVIg in a dose-dependent way. In addition, IgG purified from IVIg and its F(ab′)2 fragment neutralized LA activity of the patient’s IgG. In both cases, the neutralization was dose-dependent and it was obtained with similar molar ratios

The “in vitro” neutralization of LA activity and the immediate shortening of the APTT after IVIg infusion, might be mediated through idiotypel antiidiotype interactions.

On the other hand, the long-lasting effect of IVIg in this patient indicates that it may induce specific inhibition of autoantibody synthesis.

We believe that IVIg should be considered as a therapeutic alternative for LA-related clinical disorders.

Dedicated to Professor Marc Verstraete on the occasion of his 65th birthday.


 

  • References

  • 1 Lechner K. Acquired inhibitors in non-hemophilic patients. Haemostasis 1974; 3: 65-93
    PubMedGoogle Scholar
  • 2 Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin MA, coagulation inhibitor with phospholipid specificity: mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
    CrossrefPubMedGoogle Scholar
  • 3 Pengo V, Thiagarajan P, Shapiro S, Heine M. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 69-76
    PubMedGoogle Scholar
  • 4 Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622
    PubMedGoogle Scholar
  • 5 Lechner KA. A new type of coagulation inhibitor. Thromb Diath Haemorrh 1969; 21: 482-499
    PubMedGoogle Scholar
  • 6 Boxer M, Ellman L, Carvalho A. The lupus anticoagulant. Arthr Rheum 1976; 19: 1244-1248
    CrossrefPubMedGoogle Scholar
  • 7 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
    PubMedGoogle Scholar
  • 8 Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 1980; 92: 156-159
    CrossrefPubMedGoogle Scholar
  • 9 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Haemostas Thromb 1972; 1: 75-95
    PubMedGoogle Scholar
  • 10 Veltkamp JJ, Kerkhoven P, Loeliger EA. Circulating anticoagulant in disseminated lupus erythematosus. Haemostasis 1973; 2: 253-259
    PubMedGoogle Scholar
  • 11 Elias M, Eldor A. Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch Intern Med 1984; 144: 510-515
    CrossrefPubMedGoogle Scholar
  • 12 Rapaport SI, Ames SB, Duvall BJ. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 1960; 15: 212-227
    CrossrefPubMedGoogle Scholar
  • 13 Bowie EW, Thompson JH, Cascuzzi PA, Owen GA. Thrombosis in SLE despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
    PubMedGoogle Scholar
  • 14 Boey M, Colaco CB, Gharavi AE, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021-1023
    CrossrefPubMedGoogle Scholar
  • 15 Lechner K, Pabinger-Fasching I. Lupus anticoagulant and thrombosis. Haemostasis 1985; 15: 254-262
    PubMedGoogle Scholar
  • 16 Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand 1975; 197: 153-159
    PubMedGoogle Scholar
  • 17 Soulier JP, Boffa MC. Avortements a repetition, thrombose et anticoagulant circulant anti-thromboplastine. Nouvelle Presse Med 1980; 9: 859-864
    PubMedGoogle Scholar
  • 18 Firkin BG, Howard MA, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet 1980; 2: 366
    CrossrefPubMedGoogle Scholar
  • 19 Vermylen J, Carreras LO, Van Assche A. Repeated abortion and intrauterine death in women with a lupus anticoagulant. In: Fetal Growth Retardation Van Assche A, Robertson WB. (eds). Churchill-Livingstone; Edinburgh: 1981: 156-160
  • 20 Stiehm ER, Ashida E, Kim KS, Winston DJ, Haas A, Gale RP. Intravenous immunoglobulins as therapeutic agents. Ann Intern Med 1987; 107: 367-382
    CrossrefPubMedGoogle Scholar
  • 21 Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-768
    PubMedGoogle Scholar
  • 22 Zimmermann R, Kommerell B, Harenberg J, Eich W, Rother K, Schimpf KL. Intravenous IgG for patients with spontaneous inhibitor to factor VIII. Lancet 1985; 1: 273-274
    PubMedGoogle Scholar
  • 23 McVerry BA, Spearing R, Smith A. SLE anticoagulant: transient inhibition by high dose immunoglobulin infusions. Br J Haematol 1985; 61: 579-580
    CrossrefPubMedGoogle Scholar
  • 24 Green D, Hougie C, Kasmier FJ, Lechner K, Mannucci PM, Rizza CR, Sultan Y. Report of the Working Party on Acquired Inhibitors of Coagulation: Studies of “lupus” anticoagulant. Thromb Haemostas 1983; 49: 144-146
    PubMedGoogle Scholar
  • 25 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell Viper Venom Time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
    PubMedGoogle Scholar
  • 26 Triplett DA, Brandt JT, Kaczor D, Schaefer J. Laboratory diagnosis of lupus inhibitors : a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
    CrossrefPubMedGoogle Scholar
  • 27 Rosove MH, Ismail M, Koriol BJ, Runge A, Kosper CK. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68: 472-478
    PubMedGoogle Scholar
  • 28 Weir DM. (ed) Handbook of Experimental Immunology. Vol I.. Immunochemistry Blackwell Sci Publ; Oxford: 1973
    Google Scholar
  • 29 Lechner K. Lupus anticoagulants and thrombosis. In: Thrombosis and Haemostasis 1987 Verstraete M, Vermylen J, Lijnen HR, Amout J. (eds). International Society on Thrombosis and Haemostasis and Leuven University Press; Leuven: 1987: 525-547
  • 30 De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss and lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829-834
    CrossrefPubMedGoogle Scholar
  • 31 Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Lupus anticoagulant in pregnancy. Br J Obstet Gynecol 1984; 91: 357-363
    CrossrefPubMedGoogle Scholar
  • 32 Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with lupus anticoagulant. N Engl J Med 1985; 313: 1322-1326
    CrossrefPubMedGoogle Scholar
  • 33 Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152-156
    CrossrefPubMedGoogle Scholar
  • 34 Branch DW. Immunologic disease and fetal death. Clin Obstet Gynecol 1987; 30: 295-311
    CrossrefPubMedGoogle Scholar
  • 35 Branch DW, Dudley DJ, Daynes R, Mitchell MD, Abbott TM. IgG fractions from patients with antiphospholipid antibodies cause fetal death in Balb C mice: a new model for autoimmune abortion. Proc Soc Gynecol Invest 1989 (Abstract)
    PubMedGoogle Scholar
  • 36 Carreras LO, Defreyn G, Machin S, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-246
    PubMedGoogle Scholar
  • 37 Carreras LO, Vermylen J, Spitz B, Van Assche A. “Lupus” anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death. Br J Obstet Gynaecol 1981; 88: 890-894
    CrossrefPubMedGoogle Scholar
  • 38 Carreras LO, Vermylen JG. “Lupus” anticoagulant and thrombosis. Possible role of inhibition of prostacyclin formation. Thromb Haemostas 1982; 48: 38-40
    PubMedGoogle Scholar
  • 39 Schorer AE, Wickham NW R, Watson KV. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol 1989; 71: 399-407
    PubMedGoogle Scholar
  • 40 Carreras LO, Vermylen J. Antiphospholipid antibodies and impairment of prostacyclin synthesis by the endothelium. In: Phospholipid Binding Antibodies Harris EN, Exner T, Hughes GR V, Asherson R. (eds). CRC Press; New York: (in press)
  • 41 Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet 1983; 1: 1361-1363
    PubMedGoogle Scholar
  • 42 Feinstein DI. Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 1985; 313: 1348-1350
    CrossrefPubMedGoogle Scholar
  • 43 Frampton G, Cameron JS, Thom M, Jones S, Raftery M. Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet 1987; 2: 1023-1024
    PubMedGoogle Scholar
  • 44 Carreras LO, Perez GN, Ruda VegaH, Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 1988; 2: 393-394
    PubMedGoogle Scholar
  • 45 Mueller-Eckhardt G, Heine O, Neppert J, Kunzel W, Mueller-Eckhardt C. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin. Vox Sang 1989; 56: 151-154
    CrossrefPubMedGoogle Scholar
  • 46 Hedge UM. Immune thrombocytopenia in pregnancy and the newborn: a review. J Infect 1987; 15 (Suppl. 01) 55-58
    CrossrefPubMedGoogle Scholar
  • 47 Carreras LO, Perez GN, Xavier DL, Blanco AN, Penalva LB. Autoimmune factor VIII inhibitor responsive to gammaglobulin without in vitro neutralization. Thromb Haemostas 1988; 60: 343
    PubMedGoogle Scholar
  • 48 Bernstein RM, Crawford RJ. IVIg therapy for anticardiolipin syndrome: a case report. Proceedings Third International Symposium on Antiphospholipid Antibodies Jamaica: 1988. (Abstract 8)
    Google Scholar
  • 49 Scott JR, Branch DW, Kochenour NK, Ward K. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 1988; 159: 1055-1056
    CrossrefPubMedGoogle Scholar
  • 50 Parke A, Maier D, Wilson D, Andreoli J, Ballow M. Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med 1989; 110: 495-496
    PubMedGoogle Scholar
  • 51 Barbui T, Finazzi G, Falanga A, Cortelazzo S. Intravenous gammaglobulin, antiphospholipid antibodies, and thrombocytopenia. Lancet 1988; 2: 969
    PubMedGoogle Scholar
  • 52 Gris JC, Schved JF, Tousch D, Hereil S, Feugeras O. Anti-idiotypic antibodies against anti-phospholipid autoantibodies which suppress lupus-like anticoagulant activity. Nouv Rev Fr Hematol 1988; 30: 143-147
    PubMedGoogle Scholar
  • 53 Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti VIII (antihaemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti VIII :C autoantibodies. Proc Natl Acad Sci USA 1987; 84: 828-831
    CrossrefPubMedGoogle Scholar
  • 54 Rossi F, Dietrich G, Kazatchkine MD. Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins. Res Immunol 1989; 140: 19-31
    CrossrefPubMedGoogle Scholar